GlassScriptPhysician profile
Heather Hunley
NPI 1689174211
$3,267.15
in general payments reported to CMS, 2019-2025
22 companies · $762 in 2025
The $762 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $502 · 2022: $868 · 2023: $682 · 2024: $453 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,897.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $938.44 | 2021-2025 | |
| Novo Nordisk INC | $559.89 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $282.88 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $265.81 | 2023-2025 | Xifaxan |
| Amarin Pharma, INC. | $221.39 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $134.15 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130.67 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $129.63 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $102.72 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $89.20 | 2024-2025 | |
| Abbott Laboratories | $69.15 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.29 | 2022-2023 | Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $51.84 | 2023 | |
| Lilly USA, LLC | $50.44 | 2022-2023 | Mounjaro, Trulicity |
| Biohaven Pharmaceuticals, INC. | $37.82 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $29.12 | 2025 | Veozah |
| Mylan Specialty L.P. | $27.17 | 2023 | Yupelri |
| Eisai INC. | $27.11 | 2021-2022 | |
| Shield Therapeutics INC | $17.98 | 2023 | Accrufer |
| Merck Sharp & Dohme LLC | $15.22 | 2022 | |
| Amgen INC. | $13.29 | 2023 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $12.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Hunley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.